Yes, exactly.
We'll use Edwards as an example of what multiple of revenue the US market values a rapidly growing med tech company which operates in a duopoly....
In 2021, Edwards had sales of 5,232,500 000 (five billion, two hundred and thirty two million, five hundred thousand US$)
Edwards current market cap is $67.26 Billion.
67.26/5.2325 = 12.85
So they're trading on almost 13x revenue or sales.
Now, I'm not saying that I'd buy Edwards at that price, I wouldn't. I think they're grossly overvalued. Although this is just to illustrate how the US market values such companies.
Ann: Merger Proposal Update, page-20
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$11.76 |
Change
-0.390(3.21%) |
Mkt cap ! $248.6M | |||
| Open | High | Low | Value | Volume |
| $12.15 | $12.27 | $11.27 | $382.7K | 32.38K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 420 | $11.75 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $11.85 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |